Patient-level analysis of the cost and variation in melatonin prescribing patterns in those under 18 in the North East of England Authors: Elizabeth Miriam McLellan, Iram J Haq, Anne-Marie Ebdon, Nicola Vasey, Kirstie N Anderson Published: 2024 ABSTRACT AbstractBackgroundMelatonin is widely used to promote sleep in both normally developing children and adolescents and those with neurodevelopmental disorders. It has an evidence base as both hypnotic and chronobiotic although the optimum dose and timing remain unclear. There are now a wide variety of different preparations of melatonin both immediate and prolonged release. We reviewed annual national and regional prescribing data and undertook a detailed review of one year of melatonin prescriptions issued to those under 18 within one of the UK’s dedicated paediatric hospitals, this included a cost analysis. This was to understand whether prescribing was appropriate, whether behavioural therapies had been recommended first and whether there had been consideration of other causes of poor sleep, such as sleep apnoea.MethodsBetween November 2020 and October 2021, 220 patients under 18 had one or more melatonin prescriptions issued to treat poor sleep. The audit assessed whether prescriptions were issued in accordance with local Melatonin Shared Care Guidance standards that emphasise: an initial behavioural approach, fixed timing, use of licensed preparations and review of benefit. This included a detailed review of electronic patient care records. A cost analysis of the different preparations was also made.Results adherence to the audit were not met for any of the audit standards, only 9% had a prior behavioural intervention, and only 15% had another sleep disorder considered. Community prescribers were more likely to give advice on timing and review any subsequent benefit. The total costs of prescriptions were £13 299 of which £8736 was issued as off licence, liquid suspension.ConclusionThe audit highlighted a lack of knowledge about appropriate melatonin prescribing and led to a trust-wide sleep education programme. It additionally highlighted the cost and potential risk of inappropriate prescribing and a clear need for better access to effective behavioural interventions.Keywords: Sleep, Pharmacology WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS This study reviews cost, safety and appropriateness of secondary care paediatric prescribing in the North East of England. Melatonin prescribing was often inappropriate and involved costly liquid preparations suggesting prescribers were unaware of both cost and the benefit of behavioural intervention for sleep disorders. This study reviews cost, safety and appropriateness of secondary care paediatric prescribing in the North East of England. Melatonin prescribing was often inappropriate and involved costly liquid preparations suggesting prescribers were unaware of both cost and the benefit of behavioural intervention for sleep disorders. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Increased awareness of both the cost and benefit of melatonin, relevant guidelines and the benefit of behavioural interventions for children with poor sleep is needed within paediatrics. Increased awareness of both the cost and benefit of melatonin, relevant guidelines and the benefit of behavioural interventions for children with poor sleep is needed within paediatrics. Introduction Children and adolescents can experience transient sleep disturbance alongside other medical problems, but there are also specific sleep disorders that require investigation and may need therapy. Sleep disorders place a significant burden on those under 18 with immediate and long-term cognitive and metabolic impact and also cause parental distress.1 The most prevalent sleep disorder is behavioural pattern insomnia typically encompassing bedtime resistance, difficulty initiating and maintaining sleep, often with returns to the parental bedroom. There is good evidence for behavioural interventions in childhood insomnia in those with or without neurodevelopmental disorders2 3 followed by pharmacological intervention if these measures fail.4 Other sleep disorders include obstructive sleep apnoea, parasomnia and narcolepsy. The limited access to sleep medicine training in the UK and to paediatric sleep services can be a barrier to appropriate management and prescribing for sleep disorders. Melatonin is often described as the ‘hormone of darkness’, secreted by the pineal gland and rising at night as light levels fall with an effect on the timing and stability of sleep.5 Exogenous melatonin is a prescription only medicine in the UK with an evidence base for paediatric sleep disorders, in particular for those with circadian rhythm disorders such as delayed sleep phase syndrome. The American Academy of Neurology guidelines6 and a recent Melatonin consensus statement from the International Paediatric Sleep Association (IPSA) (https://ipsapedsleep.wildapricot.org/Melatonin-TaskForce) highlight benefit for sleep onset, particularly in those with neurodevelopmental disorders where randomised controlled trials show benefit compared with placebo.4 7 The benefits are less clear in normally developing children.8 It is not recommended or licensed for use under 2 years of age. Melatonin is a light sensitive hormone suppressed by daylight or blue light from screen use, hence the need for appropriate education around use. It is widely perceived as safe with little potential for dependence or tolerance but can cause dizziness, nausea, headache and morning sleepiness, particularly at higher doses. The number of prescriptions for melatonin has increased exponentially in primary care in England in the last 10 years with substantial regional variation across the UK.9 This has a substantial cost, particularly with unlicensed liquid preparations; therefore, patient-level analysis of prescribing is needed. We therefore performed a detailed analysis of melatonin prescribing to understand whether prescribing was appropriate, whether behavioural therapies are recommended first and whether other sleep disorders are considered. Method We reviewed national and regional prescribing data of melatonin issued over a 12-month period November 2020 to October 2021. We then undertook a detailed case notes review of all melatonin prescriptions issued to those under 18 years within a large UK paediatric hospital over this time. This included initiation and subsequent follow-up of all community and in-patient prescriptions, including timing, dose and whether appropriate behavioural therapies had been documented and whether there had been consideration of other causes of poor sleep apart from insomnia, for example, obstructive sleep apnoea. A cost analysis was included and a detailed breakdown of the cost of licensed and unlicensed preparations. This was aimed at understanding whether prescribing was appropriate, safe and cost effective. Hospital pharmacy staff provided a complete list of every melatonin prescription issued from the Great North Children’s Hospital (GNCH) from the 12 months of November 2020 until the end of October 2021. GNCH is one of the UK’s largest paediatric hospitals with both in-patients and community and hospital-based outpatient clinics but distinct from child and adolescent mental health services. GNCH has a dedicated paediatric sleep service that provides education around insomnia and sees child and adolescent sleep disorders. The data reported relates to children and adolescents who were 18 years of age or younger. Audit standards were based on both the British National Formulary for children and the North of Tyne, Gateshead and North Cumbria Area Prescribing Committee Melatonin Shared Care Guidance.10,11 We wanted to establish whether paediatricians in GNCH were prescribing melatonin in accordance with the guidance. In addition, audit standards were derived from good practice recommendations in the use of melatonin for sleep problems in children with neurodevelopmental disorders published in The Drug and Therapeutics Bulletin.12 These local shared guidelines require all melatonin prescriptions to be initiated by a paediatrician, hospital or community based or relevant secondary care specialist (online supplemental file 1). Prescribers should consider different causes of poor sleep and ensure appropriate sleep hygiene measures are first established. If the child is struggling with sleep onset despite behavioural advice, only then initiate melatonin at a fixed dose and with advice on timing and subsequent review to check effectiveness and adjust dose as necessary to improve sleep onset. Patients continued response, and tolerability to treatment should be reviewed every 6 months, alongside ongoing behavioural sleep advice, giving regular medication breaks to consider whether the melatonin remains of benefit and to conduct a formal review after 2 years of treatment. The guidelines also specify the avoidance of high-cost liquid preparations in those without swallowing difficulties and, for safety, avoidance of use under the age of 2. Individual hospital records and primary care records were reviewed for each patient using the available Great North Care Record. Data were collected on the melatonin prescriptions, including formulation, dosage and duration of prescription. This included review for at least 3 months beyond the initiation of the medication. The following details were recorded if present in the records (see table 1). Table 1Case notes documentation for those issued melatonin prescriptionsDocumentation within electronic patient recordYesall prescribersn=220YesCommunity prescribern=155YesIn-patient prescribern=65Habitual bedtime152 (69%)145 (94%)7 (11%)Bedtime routine101 (46%)101 (65%)0 (0 %)Prior or current behavioural input20 (9%)19 (12%)1 (2%)Light levels/screen in bedroom11 (5%)11 (7%)0 (0%)Timing recommendation123 (55%)120 (77%)3 (5%)Consideration of sleep apnoea32 (14.5%)29 (19%)3 (5%)Dose reviews74 (34%)67 (43%)7 (11%)Break/initiation of break57 (26%)50 (32%)7 (11%) Case notes documentation for those issued melatonin prescriptions Whether the child had a neurodevelopmental disorder. Whether the child had a neurodevelopmental disorder. Consideration of other sleep disorders such as obstructive sleep apnoea. Consideration of other sleep disorders such as obstructive sleep apnoea. Documentation of current bedtime, bedtime routine, light levels and screen use. Documentation of current bedtime, bedtime routine, light levels and screen use. Documentation of prior behavioural input. Documentation of prior behavioural input. Recommendations about medication timing. Recommendations about medication timing. Review of the dose or recommendation for medication break. Review of the dose or recommendation for medication break. Clinicians and pharmacy staff collected the audit data. Ethical approval is not required for audit-based quality and improvement initiatives, and the decision tool of the health research authority was followed,13 but this was registered within the trust as an audit, following standard clinical governance procedures when accessing the Great North Care Record. Patient and public involvement No patient involved. Results In total, across the National Health Service (NHS) in England, 1 352 145 melatonin prescriptions were issued at a cost of £47 744 413 million over the year of the study (data November 2020–October 2021).14 The NHS in England is divided into nine geographical regions, and within the North East and Yorkshire region, there were 215 518 melatonin prescriptions issued at a cost of £8 870 201 million, making up 16% of the total issues.14 This included all formulations of melatonin issued to adults and children. In total, there were 298 individual patients that had melatonin prescriptions from the pharmacy from GNCH between 213 October 2020 and 30 September 2021. Of these, 78 were single issue prescriptions for sedation used for an in-patient investigation; these were therefore excluded. This left a total of 220 patients for the audit who had at least 28 days or one or more prescriptions of melatonin used to treat poor sleep. The majority of prescriptions were issued in the community with 155 outpatients; 65 were hospital in-patients. Of the 220 patients (89 female/131 male), the age range was 0 to 18. Six prescriptions were issued to infants under the age 1, and 18 prescriptions issued to children aged 1–2 years of age. 137 (62%) were documented as having one or more neurodevelopmental disorder (ASD/ADHD/any listed learning disability). Documentation of bedtime, bedtime routine, timing recommendation and consideration of other sleep disorders The results are summarised for the 220 patient records in table 1. In summary, none of the audit standards were met. Only 69% of caregivers/patients were asked about bedtime and whether this was age appropriate. In 54% of cases, there was no documentation that bedtime routine, light levels or use of screens had been discussed, or, for example, whether the child self-settled, this included the primary care records. We looked at whether prescribers asked about ‘lights off’ timing—this was documented in 5% patients. Only 9% of patients had documentation of a prior behavioural intervention; this included any mention of the words ‘sleep hygiene’. Timing recommendations for melatonin were documented in 55% of patients. Recent consensus guidelines recommend taking melatonin 30–60 min before bed as most beneficial for aiding sleep onset. Consideration of symptoms of sleep apnoea as a possible alternative cause of poor sleep was rarely documented; this included any mention of snore, tonsil size and noisy breathing at night. Obstructive sleep apnoea in children causes a fragmented night and behavioural change and requires specific and separate investigations to confirm the diagnosis. Subsequent follow-up clinic visits were reviewed to see whether there was documented benefit of the medication and/or a long-term dosing plan based on the benefit. A benefit was documented in 33%. Of the 220 patients audited, a long term plan was discussed in 26%. There was a marked difference in documentation in melatonin prescribed in inpatients compared with paediatricians working in outpatient community settings as shown in table 1. Children seen in the community services more frequently had advice around dose, timing and reviews in medications, and there was more documentation recommending breaks in treatment. Formulation of melatonin issued A very wide variety of different melatonin prescriptions are issued as detailed in table 2. The majority of melatonin prescriptions issued were liquid suspension alone (95/220), according to the Shared Care Guidelines; this should only be issued as Third line—‘only if crushed tablets have been trialled first and are unsuitable’. In some cases, liquid was initiated followed by a trial of tablets/capsules. One safety issue is that some melatonin liquid is unsuitable for under 5 due to propylene glycol content. Liquid suspension was issued to children aged between 0 and 18 years, although none under 5 were given preparations containing propylene glycol. Only 13 of the children required PEG feeding. Therefore, most children should have been issued with either suspension or crushed tablets. An additional 30 patients were prescribed a combination of both suspension and various other formulations issued (tablets and capsules). There is no evidence base to support combinations of different preparation of melatonin in the same individual. For 10 children, this meant that the total dose was above the maximum 12 mg recommended. Table 2Variation in both dosing and preparations of melatonin issued in the 220 patients issued melatoninMelatonin formulationTotal numberCircadin 2 mg P/R tablets42Slenyto 1 mg P/R tablets*18 (5 via PEG)Slenyto 5 mg P/R tablets*1Melatonin 2 mg capsules19 (3 via PEG)Melatonin 5 mg capsules4Melatonin 2 mg and 5 mg capsules2Melatonin 1 mg and 2 mg P/R tablets2Oral suspension 1 mg/mL102 (5 via PEG)Melatonin suspension and 1 mg or 2 mg P/R tablets21Melatonin suspension and 2 mg or 5 mg capsules8Melatonin suspension 1 mg P/R tablet and 2 mg capsules1Total220*Current licensed preparations.PEGPercutaneous gastrostomyP/Rprolonged-release Variation in both dosing and preparations of melatonin issued in the 220 patients issued melatonin Current licensed preparations. PEGPercutaneous gastrostomyP/Rprolonged-release Cost analysis The amount spent on the different melatonin preparations was calculated by pharmacy based on cost price of medication supplied to the hospital at the start of the audit. This is shown in table 3 and highlights the wide variation in the cost of different preparations of melatonin available within the UK with the most costly prescribing being oral solution at £8730. The total cost of annual prescriptions issued from the trust was £13, 299. This does not include ongoing community costs. Table 3The cost of the different melatonin preparations used between November 2020 and October 2021 at time of issueFormulationSum of issue valueMelatonin PG free 1 mg in 1 mL oral solution£8730.84Melatonin 1 mg in 1 mL suspension£5.40Melatonin 2 mg capsules£457.00Melatonin 5 mg capsules£168.93Melatonin 1 mg prolonged release tablets£677.70Melatonin 2 mg capsules£1041.90Melatonin 2 mg prolonged release tablets£1126.82Melatonin 5 mg capsules£990.57 Total £13 299.16 PGpropylene glycol free The cost of the different melatonin preparations used between November 2020 and October 2021 at time of issue PGpropylene glycol free Discussion We report a detailed, retrospective case notes audit of melatonin prescribing practice over 12 months in a UK paediatric hospital. The use of melatonin across the UK is rising rapidly with over 1.3 million prescriptions issued nationally. There is significant regional variation in primary care prescribing.9 14 The choice of melatonin preparations has also increased. At the point of the audit, there was only a single modified release melatonin preparation licensed for use in children, only licensed for use in those with ASD and Smith-Magenis syndrome (Slenyto). Since the audit and from 2022, an immediate release preparation is now available for those aged 6–17 and with ADHD; this highlights the difficulty that many prescribers will face with a normally developing child with either a delayed sleep phase syndrome or behavioural pattern insomnia where behavioural measures have failed. The audit highlighted that established guidelines around safe and effective melatonin prescribing were not being followed and that a wide variety of different preparations were being used with cost analysis showing a high cost to unlicensed, liquid preparations. Melatonin was used in those under 2 years of age and multiple doses in the same child despite a lack of any published guidelines to support this. A strength of the current study is patient-level detailed notes review with additional cost analysis. In particular, high use of liquid preparations led to unnecessary cost and in those under the age of 2—potential risk given that some oral solutions are not recommended in infants due to the propylene glycol content. Limitations include a single centre study which may not therefore be applicable UK wide. However, this allowed a complete dataset using both the hospital pharmacy and with access to all hospital and primary care records. This study complements a recent retrospective study reviewing UK mental health prescribing to those under 18.15 These did not include patient-level cost analysis or consider other sleep disorders but in contrast found 2/3 prescribers reporting initial behavioural intervention, although few recommended treatment breaks. This suggests that mental health professionals consider sleep hygiene recommendations more frequently than paediatricians. Consideration of other sleep disorders and behavioural intervention prior to melatonin For anyone with sleep disturbance, there is a need to consider other sleep disorders as well as insomnia or a delay in sleep onset. Only 14.5% of prescribers asked questions considering snoring and potential obstructive sleep apnoea. This may reflect general paediatric practice where children and adolescents with those disorders have already been referred to the existing specialist sleep services. However, obstructive sleep apnoea remains a common condition that presents with neurobehavioural sequelae during the day in children, and so it needs to be considered within the diagnosis of a child with disturbed night sleep and daytime dysfunction.16 Use of behavioural interventions before or alongside melatonin Behavioural interventions include graded extinction, education about normal sleep habits and timing, alongside simple sleep logs for parents and children. They have a strong evidence base for improving various aspects of sleep disturbance in different clinical populations of children and adolescents in 50–80% of those treated. These interventions can be delivered face-to-face, telephone or digitally. Clinical guidelines recommend that these interventions are tried before medication and, for some, will be sufficient to improve sleep and avoid pharmacotherapy.3 4 In our patients treated with melatonin, only 9% had a prior behavioural intervention of any kind. This proportion did not differ between those children and adolescents with or without a neurodevelopmental disorder. Those who were issued melatonin were rarely given behavioural advice alongside the prescription. There is added benefit for a cognitive behavioural therapy (CBT) in combination with melatonin. A randomised controlled trial17 randomised 160 children to receive melatonin alone, CBT alone, melatonin and CBT or placebo alone. Combination therapy of CBT and melatonin was much more effective than either treatment alone. Despite this encouraging evidence, we found that CBT was rarely tried before melatonin was prescribed or alongside melatonin. This seems likely to be lack of knowledge of CBT and/or inability to access services providing this treatment. Whether advice was given about when to stop prescribing or advice about a trial of withdrawal Only 26% of prescribers recommended a treatment break to check ongoing need and benefit. Some children using melatonin for sleep disturbance in the absence of neurodevelopmental disorders can successfully withdraw medication.18 The shared care regional guidelines therefore recommend that melatonin that is being used as a treatment for delayed sleep-wake phase disorder should be stopped at least once every 6 months to check if it is still needed. There is a lack of research testing the risks and benefits of such treatment breaks across different clinical populations that prescribed melatonin, and the national formulary guidelines do not mention this.12 However, the international consensus guidelines recommend annual treatment breaks, and many NHS Trusts guidelines endorse treatment break strategies. Variation in melatonin formulation issued Despite shared care guidelines highlighting use of licensed preparations, there was widespread use of both a range of different strengths and liquid formulations in those with normal swallow (only 13 liquid prescriptions issued were for those requiring PEG feeding). Many prescribers are unaware of the added excipient within some liquid preparations which can potentially add risk if given to very young children. Propylene glycol is added as excipient to melatonin liquid, and higher doses in infants can cause side effects, and accidental overdose can rarely cause toxicity.19 Use of liquid preparations has significant cost implications for long-term prescribing. The potential cost saving from use of licensed preparations may be money better spent educating health professionals in behavioural sleep interventions.20 This audit informed an ongoing hospital-wide sleep education programme and patient and caregiver behavioural advice now available within the GNCH trust intranet and aligned to the Regional Healthier Together website.21 A unified approach to community and hospital behavioural interventions for sleep alongside melatonin prescribing would improve education around sleep disorders and sleep outcomes for children, adolescents and caregivers. While melatonin is effective for some children both with and without neurodevelopmental disorders, there is an unmet need for better understanding of all sleep disorders and for safe and cost-effective prescribing. supplementary material Acknowledgements Thanks are due to all the clinicians and clinical audit staff from the GNCH who helped with this audit and quality improvement initiative. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants. Ethical approval is not required for audit-based quality and improvement initiatives, and the decision tool of the health research authority was followed, but this was registered within the trust as an audit. All data were obtained from hospital pharmacy staff; no patient identifiable data were used at any point within the manuscript. Data availability free text: De-identified data was analysed within trust computers and using existing electronic medical record available within the Great North care record.Therefore, appropriate health professionals with the relevant clinical trust governance guidelines in place could liaise for further detail if required. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Contributor Information Elizabeth Miriam McLellan, Email: e.mclellan1@nhs.net. Iram J Haq, Email: iram.haq@newcastle.ac.uk. Anne-Marie Ebdon, Email: anne-marie.ebdon@nhs.net. Nicola Vasey, Email: n.vasey@nhs.net. Kirstie N Anderson, Email: kirstieanderson@nhs.net. Data availability statement Data are available upon reasonable request. References Supplementary Materials Data Availability Statement Data are available upon reasonable request.